Proteomics International Laboratories (PIQ) Investor Presentation summary

Commercial launch and product pipeline

• Four first-in-class diagnostic tests launching in FY26 across Australia and the USA, targeting diabetic kidney disease, endometriosis, esophageal cancer, and oxidative stress-related muscle damage.

• Tests validated in large clinical studies, offering significant advantages over current standards of care and addressing large unmet medical needs.

• Consumer-driven strategy focuses on primary care and GP clinics, supported by a digital platform and engagement with key opinion leaders.

• Commercial ramp-up underway for PromarkerD and PromarkerEso, with initial sales achieved and further launches planned.

• Patented products and attractive margins position the company for licensing agreements and strategic partnerships.

Market strategy and partnerships

• Emphasis on building market awareness and adoption through digital and traditional channels, targeting both end users and potential licensing partners.

• Reimbursement pricing for PromarkerD in the USA is imminent, with other tests to follow, supporting near-term revenue growth.

• Flexible partnering options include non-exclusive and exclusive licensing, with ongoing discussions with global health and diagnostic companies.

• Platform and infrastructure enable rapid tech transfer and product launch, enhancing attractiveness for partners.

• Industry and government focus on precision medicine creates additional demand for novel diagnostics.

Financial and operational highlights

• Market capitalisation of A$67m as of December 2025, with A$12.7m in cash and a recent A$12m capital raise completed.

• Quarterly cash receipts of A$1.8m and cash burn of A$1m in Q1 FY26, supported by a revenue-generating bioanalytical services business.

• State-of-the-art laboratories and a US CLIA-certified reference lab established, with headquarters in Perth, WA.

• Top 40 shareholders hold 41% of shares, with directors holding 11%, indicating strong alignment.

• Fully funded to execute launch strategies and drive commercialisation in FY26.